Skip to main content

Table 1 Demographic and clinical features of training set and validation set in the present study

From: Different expression pattern of human cytomegalovirus-encoded microRNAs in circulation from virus latency to reactivation

Variable Training set Validation set
Viremia (n = 23) Control (n = 24) P values Viremia (n = 36) Control (n = 36) P values
Age, yearsa 44.1 ± 4.0 51.9 ± 3.6 0.15 52.8 ± 3.3 49.7 ± 3.2 0.50
Sex, n    0.19§    0.48§
 Male 9 (39.1%) 14 (58.3%)   19 (52.8%) 16 (44.4%)  
 Female 14 (60.9%) 10 (41.7%)   17 (47.2%) 20 (55.6%)  
HCMV DNA Levelb 1920 (1100, 3680)   1995 (795.5, 9995)  
Anti-HCMV IgG (IU/mL)a 1.59 ± 0.16 1.74 ± 0.19 0.57 1.94 ± 0.16 1.63 ± 0.15 0.17
Anti-HCMV IgM, n
 Positive 0 (0%) 0 (0%)   0 (0%) 0 (0%)  
 Negative 23 (100%) 24 (100%)   36 (100%) 36 (100%)  
HCV, n
 Positive 0 (0%) 0 (0%)   0 (0%) 0 (0%)  
 Negative 23 (100%) 24 (100%)   36 (100%) 36 (100%)  
EB, n    0.19§    0.47§
 Positive 11 (47.8%) 16 (66.7%)   13 (36.1%) 16 (44.4%)  
 Negative 12 (52.2%) 8 (33.3%)   23 (63.9%) 20 (55.6%)  
HIV, n
 Positive 0 (0%) 0 (0%)   0 (0%) 0 (0%)  
 Negative 23 (100%) 24 (100%)   36 (100%) 36 (100%)  
Leukemia, n    0.61§    1§
 Yes 7 (30.4%) 9 (37.5%)   13 (36.1%) 13 (36.1%)  
 No 16 (69.6%) 15 (62.5%)   23 (63.9%) 23 (63.9%)  
Autoimmune diseases, n    0.81§    0.44§
 Yes 6 (26.1%) 7 (29.2%)   9 (25%) 12 (33.3%)  
 No 17 (73.9%) 17 (70.8%)   27 (75%) 24 (66.7%)  
  1. Student t test
  2. §Two-sided χ2 test
  3. aAge data and anti-HCMV IgG are presented as the mean ± SD
  4. bHCMV DNA level are presented as median (25% Percentile, 75% Percentile)